Brief: Cantargia Presents Positive Results For Nadunolimab At Aacr 2023 Including New Clinical Data In Pancreatic Cancer
14/03/2023 22:46
March 14 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA PRESENTS POSITIVE RESULTS FOR NADUNOLIMAB AT
AACR 2023
INCLUDING NEW CLINICAL DATA IN PANCREATIC CANCER
* CANTARGIA AB - RESULTS FROM PHASE I/IIA CLINICAL TRIAL
CANFOUR
HAVE SHOWN STRONGER EFFICACY OF COMBINATION THAN EXPECTED FROM
CHEMOTHERAPY ALONE
Source text for Eikon: ID:nPreP11wqa
Further company coverage: CANTA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML